Myovant Sciences

$22.94
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.49 (-6.09%) As of 6:26 PM UTC today

Why Robinhood?

You can buy or sell MYOV and other stocks, options, and ETFs commission-free!

About MYOV

Myovant Sciences Ltd., also called Myovant Sciences, is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of women's health and endocrine diseases. The company's product includes relugolix, which is an oral, once-daily and small molecule that acts as a GnRH receptor antagonist. It also develops MVT-602 a kisspeptin agonist for the treatment of female infertility. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. The listed name for MYOV is Myovant Sciences Ltd.

CEO
Lynn Seely
Employees
214
Headquarters
London, Greater London
Founded
2016
Market Cap
2.09B
Price-Earnings Ratio
Dividend Yield
Average Volume
718.30K
High Today
$24.45
Low Today
$22.70
Open Price
$24.30
Volume
750.24K
52 Week High
$25.03
52 Week Low
$5.98

Collections

MYOV Earnings

-$1.07
-$0.71
-$0.36
$0.00
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Estimated
per share
Actual
Expected Feb 10, Pre-Market

You May Also Like